Kopin initiated with a Buy at Canaccord

Canaccord analyst George Gianarikas initiated coverage of Kopin (KOPN) with a Buy rating and $2 price target The firm sees a “premium multiple” for the shares as justified “by several factors.” Kopin’s defense-related opportunities appear set for growth, particularly with several projects in the funded research and development stage, and the company is also seeing expanding application opportunities in the medical and consumer markets, the analyst tells investors in a research note. Canaccord believes Kopin’s “diverse market opportunities appear set to receive a material boost through its strategic initiatives to capture a growing share of wallet.” It also sees optionality, noting the company could look to expand either through targeted acquisitions or as an acquisition target itself.